Fulgent Genetics (FLGT) Financials

$20.54 +3.29 (+19.07%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$20.33 -0.21 (-1.02%)

As of 05/2/2025 07:57 PM Eastern

Annual Income Statements for Fulgent Genetics

This table shows Fulgent Genetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	143	-168	-43
Consolidated Net Income / (Loss)	142	-175	-44
Net Income / (Loss) Continuing Operations	142	-175	-44
Total Pre-Tax Income	184	-174	-52
Total Operating Income	179	-196	-74
Total Gross Profit	367	104	107
Total Revenue	619	289	283
Operating Revenue	619	289	283
Total Cost of Revenue	252	185	176
Operating Cost of Revenue	252	185	176
Total Operating Expenses	188	300	181
Selling, General & Admin Expense	111	89	88
Marketing Expense	39	41	36
Research & Development Expense	29	41	49
Amortization Expense	6.50	7.85	7.97
Impairment Charge	0.00	120	0.00
Restructuring Charge	2.98	0.00	0.00
Total Other Income / (Expense), net	5.50	21	22
Interest Expense	-	-	-0.17
Interest & Investment Income	5.62	22	31
Other Income / (Expense), net	0.89	0.32	-9.51
Income Tax Expense	42	1.15	-8.14
Net Income / (Loss) Attributable to Noncontrolling Interest	-1.48	-7.41	-1.11
Weighted Average Basic Shares Outstanding	30.10M	29.78M	30.24M
Weighted Average Diluted Shares Outstanding	30.96M	29.78M	30.24M
Weighted Average Basic & Diluted Shares Outstanding	29.52M	29.78M	30.83M

This table shows Fulgent Genetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	1.72	-24	-15	-11	-13	-128	-13	-8.71	-15	-5.89
Consolidated Net Income / (Loss)	1.34	-24	-16	-12	-13	-134	-14	-9.09	-15	-6.19
Net Income / (Loss) Continuing Operations	1.34	-24	-16	-12	-13	-134	-14	-9.09	-15	-6.19
Total Pre-Tax Income	1.76	-33	-21	-15	6.86	-145	-14	-11	-19	-8.04
Total Operating Income	0.35	-37	-25	-20	0.21	-151	-22	-19	-17	-16
Total Gross Profit	46	13	19	21	40	25	22	26	27	32
Total Revenue	106	68	66	68	85	71	64	71	72	76
Operating Revenue	106	68	66	68	85	71	64	71	72	76
Total Cost of Revenue	60	55	47	47	45	45	42	45	45	44
Operating Cost of Revenue	60	55	47	47	45	45	42	45	45	44
Total Operating Expenses	46	50	44	40	40	176	44	45	44	48
Selling, General & Admin Expense	26	29	22	18	17	32	21	21	21	24
Marketing Expense	9.86	10	10	11	10	11	8.99	8.60	9.12	9.54
Research & Development Expense	7.51	8.51	9.78	9.69	10	12	11	13	12	12
Amortization Expense	2.01	2.01	1.97	1.96	1.96	1.96	1.99	1.99	1.99	1.99
Total Other Income / (Expense), net	1.41	3.09	3.78	5.10	6.65	5.93	7.63	7.69	-1.45	8.10
Interest & Investment Income	1.41	3.22	3.78	5.10	6.47	6.27	7.63	7.69	8.09	7.90
Income Tax Expense	0.41	-9.39	-5.20	-3.11	20	-11	-0.33	-2.12	-3.84	-1.85
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.38	-0.24	-0.51	-0.36	-0.36	-6.19	-0.38	-0.38	-0.05	-0.30
Weighted Average Basic Shares Outstanding	30.17M	30.10M	29.54M	29.81M	30.01M	29.78M	29.77M	30.10M	30.42M	30.24M
Weighted Average Diluted Shares Outstanding	30.87M	30.96M	29.54M	29.81M	30.01M	29.78M	29.77M	30.10M	30.42M	30.24M
Weighted Average Basic & Diluted Shares Outstanding	29.44M	29.52M	29.70M	29.93M	29.63M	29.78M	29.92M	30.30M	30.59M	30.83M

This table details how cash moves in and out of Fulgent Genetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-85	18	-42
Net Cash From Operating Activities	254	27	21
Net Cash From Continuing Operating Activities	254	27	21
Net Income / (Loss) Continuing Operations	142	-175	-44
Consolidated Net Income / (Loss)	142	-175	-44
Depreciation Expense	33	26	25
Amortization Expense	4.77	-3.91	-5.55
Non-Cash Adjustments To Reconcile Net Income	60	177	61
Changes in Operating Assets and Liabilities, net	14	2.82	-15
Net Cash From Investing Activities	-261	39	-58
Net Cash From Continuing Investing Activities	-261	39	-58
Purchase of Property, Plant & Equipment	-19	-22	-40
Acquisitions	-183	-0.40	0.00
Purchase of Investments	-418	-492	-472
Sale of Property, Plant & Equipment	0.41	0.78	0.31
Sale and/or Maturity of Investments	373	553	454
Other Investing Activities, net	-15	0.00	0.00
Net Cash From Financing Activities	-77	-48	-4.85
Net Cash From Continuing Financing Activities	-77	-48	-4.85
Repayment of Debt	-0.37	-4.27	-1.23
Repurchase of Common Equity	-74	-25	-0.23
Other Financing Activities, net	-2.44	-18	-3.39
Effect of Exchange Rate Changes	-0.45	-0.15	-0.06
Cash Interest Paid	0.00	0.96	0.51
Cash Income Taxes Paid	56	3.26	28

This table details how cash moves in and out of Fulgent Genetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	30	-89	-13	-7.82	26	13	-43	10	-6.93	-2.90
Net Cash From Operating Activities	21	33	-7.91	9.74	10	15	7.27	4.29	-16	25
Net Cash From Continuing Operating Activities	21	33	-7.91	9.74	10	15	7.27	4.29	-16	25
Net Income / (Loss) Continuing Operations	1.34	-24	-16	-12	-13	-134	-14	-9.09	-15	-6.19
Consolidated Net Income / (Loss)	1.34	-24	-16	-12	-13	-134	-14	-9.09	-15	-6.19
Depreciation Expense	9.82	9.80	6.88	6.31	6.42	6.53	6.66	6.15	5.92	6.19
Amortization Expense	1.01	0.54	-0.48	-0.71	-1.19	-1.53	-1.18	-1.49	-1.34	-1.55
Non-Cash Adjustments To Reconcile Net Income	17	6.87	10	15	6.67	145	9.77	17	19	15
Changes in Operating Assets and Liabilities, net	-8.58	40	-8.47	0.24	12	-0.76	5.86	-8.16	-25	12
Net Cash From Investing Activities	44	-93	-4.35	-1.10	20	24	-47	7.30	8.99	-27
Net Cash From Continuing Investing Activities	44	-93	-4.35	-1.10	20	24	-47	7.30	8.99	-27
Purchase of Property, Plant & Equipment	-5.44	-4.72	-2.03	-12	-4.92	-3.11	-4.06	-13	-20	-3.78
Purchase of Investments	-12	-146	-144	-107	-93	-148	-196	-63	-115	-98
Sale and/or Maturity of Investments	61	108	141	117	118	176	152	83	144	75
Net Cash From Financing Activities	-35	-30	-1.10	-16	-4.47	-26	-2.81	-1.15	-0.57	-0.33
Net Cash From Continuing Financing Activities	-35	-30	-1.10	-16	-4.47	-26	-2.81	-1.15	-0.57	-0.33
Other Financing Activities, net	-0.76	-0.54	-1.10	-15	14	-16	-1.82	-0.68	-0.57	-0.33
Effect of Exchange Rate Changes	0.39	-0.28	0.03	-0.21	-0.12	0.15	-0.07	-0.01	0.16	-0.13
Cash Interest Paid	-	-	0.00	0.92	0.02	0.02	0.44	0.01	0.01	0.05
Cash Income Taxes Paid	1.20	0.01	1.68	0.96	0.06	0.56	1.31	0.60	25	0.95

This table presents Fulgent Genetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	1,386	1,235	1,220
Total Current Assets	628	508	354
Cash & Equivalents	80	97	55
Short-Term Investments	447	327	203
Accounts Receivable	53	51	69
Other Current Assets	49	33	26
Plant, Property, & Equipment, net	81	83	106
Total Noncurrent Assets	677	644	761
Long-Term Investments	339	444	570
Goodwill	143	22	22
Intangible Assets	151	143	135
Other Noncurrent Operating Assets	44	35	33
Total Liabilities & Shareholders' Equity	1,386	1,235	1,220
Total Liabilities	116	102	91
Total Current Liabilities	88	73	73
Short-Term Debt	21	1.18	0.41
Accounts Payable	23	15	18
Accrued Expenses	25	31	24
Customer Deposits	11	23	28
Current Deferred Revenue	3.20	2.87	2.23
Other Current Liabilities	5.30	0.16	0.00
Total Noncurrent Liabilities	28	29	18
Noncurrent Deferred & Payable Income Tax Liabilities	9.84	14	11
Other Noncurrent Operating Liabilities	18	15	6.97
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,270	1,133	1,129
Total Preferred & Common Equity	1,267	1,136	1,133
Preferred Stock	0.00	0.00	0.00
Total Common Equity	1,267	1,136	1,133
Common Stock	487	502	543
Retained Earnings	801	633	590
Accumulated Other Comprehensive Income / (Loss)	-21	1.21	-0.37
Noncontrolling Interest	3.19	-2.82	-4.07

This table presents Fulgent Genetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	1,406	1,377	1,355	1,358	1,230	1,232	1,234
Total Current Assets	697	581	528	550	387	399	327
Cash & Equivalents	169	66	58	84	55	65	58
Short-Term Investments	402	438	400	384	251	247	155
Accounts Receivable	104	44	35	49	52	57	57
Other Current Assets	21	33	35	33	29	31	56
Plant, Property, & Equipment, net	82	79	88	85	87	93	107
Total Noncurrent Assets	627	717	739	723	757	740	800
Long-Term Investments	358	380	401	399	561	547	602
Goodwill	120	143	142	142	22	22	22
Intangible Assets	88	149	146	144	141	139	137
Other Noncurrent Operating Assets	61	45	49	38	33	32	39
Total Liabilities & Shareholders' Equity	1,406	1,377	1,355	1,358	1,230	1,232	1,234
Total Liabilities	124	108	91	97	103	103	99
Total Current Liabilities	103	82	65	61	76	76	74
Short-Term Debt	20	5.61	4.56	2.89	0.41	0.41	0.41
Accounts Payable	14	22	21	16	20	20	20
Accrued Expenses	25	21	22	21	26	26	24
Customer Deposits	26	12	14	19	27	26	27
Current Deferred Revenue	2.60	2.73	2.60	2.59	2.76	2.74	2.97
Other Current Liabilities	14	19	0.36	0.28	0.00	0.00	0.00
Total Noncurrent Liabilities	22	26	26	35	27	28	25
Noncurrent Deferred & Payable Income Tax Liabilities	1.83	9.84	9.84	19	13	13	13
Other Noncurrent Operating Liabilities	20	16	17	16	14	14	12
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,281	1,269	1,263	1,262	1,127	1,129	1,135
Total Preferred & Common Equity	1,277	1,264	1,260	1,259	1,130	1,133	1,138
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,277	1,264	1,260	1,259	1,130	1,133	1,138
Common Stock	478	496	506	514	511	522	533
Retained Earnings	825	786	774	761	620	611	596
Accumulated Other Comprehensive Income / (Loss)	-26	-17	-21	-17	-1.10	-0.88	9.18
Noncontrolling Interest	4.35	4.47	3.56	3.14	-3.30	-3.70	-3.55

This table displays calculated financial ratios and metrics derived from Fulgent Genetics' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	-37.64%	-53.28%	-1.99%
EBITDA Growth	-68.78%	-179.77%	62.97%
EBIT Growth	-73.46%	-208.80%	57.26%
NOPAT Growth	-72.55%	-199.41%	62.20%
Net Income Growth	-71.97%	-223.47%	74.99%
EPS Growth	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-52.93%	-89.35%	-22.01%
Free Cash Flow Firm Growth	-111.56%	146.06%	-492.19%
Invested Capital Growth	77.44%	-37.38%	13.07%
Revenue Q/Q Growth	-22.91%	0.98%	2.06%
EBITDA Q/Q Growth	-45.60%	-223.97%	66.14%
EBIT Q/Q Growth	-50.97%	-141.12%	60.06%
NOPAT Q/Q Growth	-48.61%	-141.51%	64.62%
Net Income Q/Q Growth	-47.37%	-169.68%	74.52%
EPS Q/Q Growth	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-14.75%	-40.36%	91.89%
Free Cash Flow Firm Q/Q Growth	-198.91%	126.87%	-27.02%
Invested Capital Q/Q Growth	14.12%	-33.11%	-5.90%
Profitability Metrics	-	-	-
Gross Margin	59.28%	36.12%	37.82%
EBITDA Margin	35.03%	-59.81%	-22.60%
Operating Margin	28.84%	-67.61%	-26.08%
EBIT Margin	28.99%	-67.50%	-29.43%
Profit (Net Income) Margin	22.93%	-60.59%	-15.46%
Tax Burden Percent	77.12%	100.66%	84.34%
Interest Burden Percent	102.57%	89.18%	62.28%
Effective Tax Rate	22.88%	0.00%	0.00%
Return on Invested Capital (ROIC)	41.41%	-39.58%	-18.24%
ROIC Less NNEP Spread (ROIC-NNEP)	40.94%	-35.10%	-19.17%
Return on Net Nonoperating Assets (RNNOA)	-29.76%	25.00%	14.36%
Return on Equity (ROE)	11.65%	-14.58%	-3.87%
Cash Return on Invested Capital (CROIC)	-14.41%	6.38%	-30.51%
Operating Return on Assets (OROA)	13.47%	-14.89%	-6.80%
Return on Assets (ROA)	10.65%	-13.37%	-3.57%
Return on Common Equity (ROCE)	11.60%	-14.58%	-3.89%
Return on Equity Simple (ROE_SIMPLE)	11.20%	-15.42%	-3.87%
Net Operating Profit after Tax (NOPAT)	138	-137	-52
NOPAT Margin	22.24%	-47.33%	-18.25%
Net Nonoperating Expense Percent (NNEP)	0.48%	-4.48%	0.93%
Return On Investment Capital (ROIC_SIMPLE)	10.67%	-12.06%	-4.58%
Cost of Revenue to Revenue	40.72%	63.88%	62.18%
SG&A Expenses to Revenue	17.95%	30.77%	31.08%
R&D to Revenue	4.67%	14.33%	17.22%
Operating Expenses to Revenue	30.43%	103.72%	63.90%
Earnings before Interest and Taxes (EBIT)	179	-195	-83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	217	-173	-64
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.69	0.75	0.50
Price to Tangible Book Value (P/TBV)	0.90	0.88	0.58
Price to Revenue (P/Rev)	1.42	2.96	1.99
Price to Earnings (P/E)	6.11	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	16.36%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.08	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.06	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.16	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.20	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.26	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.14	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.02	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.73	-0.71	-0.75
Leverage Ratio	1.09	1.09	1.09
Compound Leverage Factor	1.12	0.97	0.68
Debt to Total Capital	1.60%	0.10%	0.04%
Short-Term Debt to Total Capital	1.60%	0.10%	0.04%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.25%	-0.25%	-0.36%
Common Equity to Total Capital	98.15%	100.14%	100.32%
Debt to EBITDA	0.10	-0.01	-0.01
Net Debt to EBITDA	-3.90	5.01	12.93
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.15	-0.01	-0.01
Net Debt to NOPAT	-6.13	6.33	16.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	6.68	5.89	4.69
Noncontrolling Interest Sharing Ratio	0.42%	0.02%	-0.30%
Liquidity Ratios	-	-	-
Current Ratio	7.13	6.96	4.85
Quick Ratio	6.57	6.51	4.49
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-48	22	-87
Operating Cash Flow to CapEx	1,380.60%	125.99%	52.65%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.46	0.22	0.23
Accounts Receivable Turnover	6.46	5.57	4.72
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	8.62	3.51	3.00
Accounts Payable Turnover	11.57	9.61	10.45
Days Sales Outstanding (DSO)	56.51	65.55	77.36
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	31.56	37.98	34.92
Cash Conversion Cycle (CCC)	24.95	27.57	42.44
Capital & Investment Metrics	-	-	-
Invested Capital	425	266	301
Invested Capital Turnover	1.86	0.84	1.00
Increase / (Decrease) in Invested Capital	186	-159	35
Enterprise Value (EV)	35	-13	-267
Market Capitalization	877	857	565
Book Value per Share	$43.03	$38.34	$37.05
Tangible Book Value per Share	$33.05	$32.77	$31.92
Total Capital	1,291	1,134	1,130
Total Debt	21	1.18	0.41
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-845	-867	-828
Capital Expenditures (CapEx)	18	21	40
Debt-free, Cash-free Net Working Capital (DFCFNWC)	34	12	23
Debt-free Net Working Capital (DFNWC)	560	436	281
Net Working Capital (NWC)	540	435	281
Net Nonoperating Expense (NNE)	-4.24	38	-7.92
Net Nonoperating Obligations (NNO)	-845	-867	-828
Total Depreciation and Amortization (D&A)	37	22	19
Debt-free, Cash-free Net Working Capital to Revenue	5.52%	4.10%	8.11%
Debt-free Net Working Capital to Revenue	90.54%	150.76%	99.16%
Net Working Capital to Revenue	87.20%	150.35%	99.01%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	0.00	29.78M	30.24M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	0.00	29.78M	30.24M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	29.78M	30.83M
Normalized Net Operating Profit after Tax (NOPAT)	140	-53	-52
Normalized NOPAT Margin	22.61%	-18.22%	-18.25%
Pre Tax Income Margin	29.73%	-60.19%	-18.33%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	52.38%	-14.30%	-0.51%

This table displays calculated financial ratios and metrics derived from Fulgent Genetics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-53.63%	-73.10%	-79.34%	-45.87%	-19.85%	4.14%	-2.54%	4.68%	-15.28%	8.10%
EBITDA Growth	-93.22%	-116.75%	-108.83%	-163.25%	-49.13%	-457.42%	11.42%	-0.27%	-487.25%	92.14%
EBIT Growth	-99.78%	-124.23%	-112.29%	-254.74%	30.11%	-313.44%	12.19%	4.51%	-5,909.61%	89.32%
NOPAT Growth	-99.78%	-124.67%	-111.32%	-234.21%	-256.13%	-313.44%	12.19%	4.51%	-2,745.98%	89.32%
Net Income Growth	-98.90%	-123.22%	-110.32%	-204.42%	-1,102.68%	-457.96%	12.64%	21.57%	-9.12%	95.39%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-86.35%	-56.92%	-104.20%	-12.48%	-50.71%	-55.03%	191.89%	-55.99%	-251.46%	67.54%
Free Cash Flow Firm Growth	-533.41%	-1,373.31%	-634.00%	77.26%	88.19%	125.17%	162.09%	355.41%	355.50%	-186.73%
Invested Capital Growth	143.34%	77.44%	74.88%	9.29%	6.83%	-37.38%	-33.26%	-33.63%	-19.62%	13.07%
Revenue Q/Q Growth	-15.71%	-35.92%	-2.27%	2.55%	24.81%	-16.75%	-8.54%	10.15%	1.01%	6.23%
EBITDA Q/Q Growth	-50.21%	-334.48%	29.72%	22.92%	140.05%	-2,669.32%	88.83%	12.75%	-54.67%	47.84%
EBIT Q/Q Growth	-97.25%	-10,484.09%	32.09%	20.25%	102.31%	-33,095.85%	85.58%	13.27%	-40.74%	39.36%
NOPAT Q/Q Growth	-97.39%	-9,609.60%	32.09%	20.25%	96.97%	-25,082.25%	85.58%	13.27%	9.66%	5.53%
Net Income Q/Q Growth	-87.90%	-1,892.70%	34.17%	26.87%	-16.19%	-897.58%	89.69%	34.35%	-61.65%	57.87%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	86.73%	59.83%	-123.81%	223.14%	5.17%	45.83%	-51.34%	-41.03%	-461.94%	261.31%
Free Cash Flow Firm Q/Q Growth	-2.63%	3.67%	12.65%	73.67%	46.70%	305.33%	115.48%	8.30%	-46.68%	-169.70%
Invested Capital Q/Q Growth	-0.24%	14.12%	-8.23%	4.61%	-2.48%	-33.11%	-2.21%	4.04%	18.11%	-5.90%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	43.63%	19.18%	28.43%	30.32%	47.05%	35.78%	34.28%	37.30%	37.32%	41.79%
EBITDA Margin	10.58%	-38.72%	-27.84%	-20.93%	6.72%	-207.24%	-25.31%	-20.05%	-30.70%	-15.07%
Operating Margin	0.33%	-53.99%	-37.52%	-29.18%	0.25%	-214.34%	-33.80%	-26.62%	-23.81%	-21.17%
EBIT Margin	0.33%	-53.99%	-37.52%	-29.18%	0.54%	-214.34%	-33.80%	-26.62%	-37.09%	-21.17%
Profit (Net Income) Margin	1.27%	-35.56%	-23.95%	-17.08%	-15.90%	-190.53%	-21.47%	-12.80%	-20.48%	-8.12%
Tax Burden Percent	76.44%	71.95%	75.30%	78.84%	-196.30%	92.52%	97.69%	81.06%	79.29%	77.02%
Interest Burden Percent	499.15%	91.55%	84.79%	74.25%	1,497.82%	96.08%	65.02%	59.31%	69.65%	49.81%
Effective Tax Rate	23.56%	0.00%	0.00%	0.00%	296.30%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.78%	-70.36%	-31.24%	-16.06%	-0.37%	-125.50%	-20.91%	-15.95%	-12.89%	-14.81%
ROIC Less NNEP Spread (ROIC-NNEP)	0.66%	-70.53%	-31.40%	-16.31%	1.10%	-122.16%	-21.07%	-16.43%	-12.56%	-15.41%
Return on Net Nonoperating Assets (RNNOA)	-0.51%	51.28%	23.94%	11.36%	-0.77%	87.01%	15.35%	11.77%	8.80%	11.54%
Return on Equity (ROE)	0.27%	-19.08%	-7.30%	-4.70%	-1.14%	-38.49%	-5.56%	-4.18%	-4.09%	-3.26%
Cash Return on Invested Capital (CROIC)	18.43%	-14.41%	-65.49%	-23.35%	-21.31%	6.38%	-1.52%	0.93%	-18.98%	-30.51%
Operating Return on Assets (OROA)	0.20%	-25.08%	-9.63%	-6.37%	0.11%	-47.30%	-7.46%	-5.98%	-7.95%	-4.89%
Return on Assets (ROA)	0.78%	-16.52%	-6.15%	-3.73%	-3.30%	-42.04%	-4.74%	-2.88%	-4.39%	-1.88%
Return on Common Equity (ROCE)	0.27%	-19.00%	-7.27%	-4.68%	-1.13%	-38.48%	-5.56%	-4.18%	-4.09%	-3.27%
Return on Equity Simple (ROE_SIMPLE)	21.12%	0.00%	-2.17%	-3.98%	-5.16%	0.00%	-15.33%	-15.08%	-15.11%	0.00%
Net Operating Profit after Tax (NOPAT)	0.27	-26	-17	-14	-0.42	-106	-15	-13	-12	-11
NOPAT Margin	0.25%	-37.79%	-26.26%	-20.42%	-0.50%	-150.04%	-23.66%	-18.63%	-16.66%	-14.82%
Net Nonoperating Expense Percent (NNEP)	0.12%	0.17%	0.16%	0.25%	-1.47%	-3.34%	0.16%	0.48%	-0.33%	0.60%
Return On Investment Capital (ROIC_SIMPLE)	-	-1.98%	-	-	-	-9.32%	-	-	-	-1.00%
Cost of Revenue to Revenue	56.37%	80.82%	71.57%	69.68%	52.95%	64.22%	65.72%	62.70%	62.68%	58.21%
SG&A Expenses to Revenue	24.86%	42.53%	32.95%	26.52%	20.66%	44.97%	33.32%	30.02%	29.20%	31.94%
R&D to Revenue	7.11%	12.57%	14.78%	14.28%	11.82%	16.95%	17.73%	18.99%	16.42%	15.89%
Operating Expenses to Revenue	43.29%	73.17%	65.95%	59.50%	46.80%	250.12%	68.08%	63.91%	61.12%	62.96%
Earnings before Interest and Taxes (EBIT)	0.35	-37	-25	-20	0.46	-151	-22	-19	-27	-16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	11	-26	-18	-14	5.69	-146	-16	-14	-22	-11
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.90	0.69	0.73	0.87	0.64	0.75	0.57	0.52	0.58	0.50
Price to Tangible Book Value (P/TBV)	1.08	0.90	0.95	1.13	0.82	0.88	0.67	0.60	0.67	0.58
Price to Revenue (P/Rev)	1.44	1.42	2.53	3.58	2.79	2.96	2.24	2.02	2.37	1.99
Price to Earnings (P/E)	4.25	6.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	23.54%	16.36%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.67	0.08	0.12	0.61	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.31	0.06	0.13	0.81	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.63	0.16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.68	0.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.93	0.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.84	0.14	0.83	4.45	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	5.15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.02	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.77	-0.73	-0.76	-0.70	-0.70	-0.71	-0.73	-0.72	-0.70	-0.75
Leverage Ratio	1.12	1.09	1.10	1.09	1.09	1.09	1.09	1.08	1.08	1.09
Compound Leverage Factor	5.60	1.00	0.93	0.81	16.28	1.05	0.71	0.64	0.75	0.54
Debt to Total Capital	1.57%	1.60%	0.44%	0.36%	0.23%	0.10%	0.04%	0.04%	0.04%	0.04%
Short-Term Debt to Total Capital	1.57%	1.60%	0.44%	0.36%	0.23%	0.10%	0.04%	0.04%	0.04%	0.04%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.33%	0.25%	0.35%	0.28%	0.25%	-0.25%	-0.29%	-0.33%	-0.31%	-0.36%
Common Equity to Total Capital	98.09%	98.15%	99.21%	99.36%	99.52%	100.14%	100.26%	100.29%	100.28%	100.32%
Debt to EBITDA	0.05	0.10	-0.51	-0.10	-0.05	-0.01	0.00	0.00	0.00	-0.01
Net Debt to EBITDA	-2.28	-3.90	79.84	17.94	16.18	5.01	5.06	5.01	4.31	12.93
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.08	0.15	-0.17	-0.08	-0.05	-0.01	0.00	0.00	0.00	-0.01
Net Debt to NOPAT	-3.39	-6.13	26.03	15.11	15.24	6.33	6.43	6.40	5.57	16.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	7.47	6.16	6.57	8.62	6.40	6.01	4.92	4.60	5.07	4.88
Noncontrolling Interest Sharing Ratio	0.52%	0.42%	0.44%	0.37%	0.29%	0.02%	0.05%	-0.01%	-0.02%	-0.30%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.79	7.13	7.09	8.15	8.95	6.96	5.09	5.27	4.41	4.85
Quick Ratio	6.59	6.57	6.69	7.61	8.42	6.51	4.71	4.86	3.65	4.49
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-219	-211	-184	-49	-26	53	115	124	66	-46
Operating Cash Flow to CapEx	398.54%	729.82%	-430.66%	81.66%	208.94%	538.90%	191.31%	33.15%	-79.54%	662.20%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	-369.82	0.00	0.00	0.00	4,724.34	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	146.29	0.00	0.00	0.00	-1,107.79	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	76.27	0.00	0.00	0.00	-2,500.57	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.62	0.46	0.26	0.22	0.21	0.22	0.22	0.22	0.21	0.23
Accounts Receivable Turnover	7.14	6.46	3.58	3.66	3.73	5.57	6.01	6.36	5.21	4.72
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	11.31	8.62	4.94	3.54	3.43	3.51	3.47	3.21	2.89	3.00
Accounts Payable Turnover	13.19	11.57	9.69	7.24	12.84	9.61	8.62	8.75	9.96	10.45
Days Sales Outstanding (DSO)	51.14	56.51	101.94	99.81	97.77	65.55	60.68	57.37	70.04	77.36
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	27.67	31.56	37.68	50.42	28.43	37.98	42.33	41.73	36.65	34.92
Cash Conversion Cycle (CCC)	23.46	24.95	64.26	49.39	69.34	27.57	18.36	15.64	33.39	42.44
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	373	425	390	408	398	266	260	271	320	301
Invested Capital Turnover	3.05	1.86	1.19	0.79	0.74	0.84	0.88	0.86	0.77	1.00
Increase / (Decrease) in Invested Capital	220	186	167	35	25	-159	-130	-137	-78	35
Enterprise Value (EV)	249	35	47	248	-60	-13	-226	-274	-160	-267
Market Capitalization	1,154	877	922	1,100	800	857	643	587	658	565
Book Value per Share	$42.19	$43.03	$42.84	$42.41	$42.06	$38.34	$37.96	$37.85	$37.58	$37.05
Tangible Book Value per Share	$35.32	$33.05	$32.95	$32.70	$32.49	$32.77	$32.48	$32.47	$32.32	$31.92
Total Capital	1,302	1,291	1,275	1,268	1,265	1,134	1,127	1,129	1,135	1,130
Total Debt	20	21	5.61	4.56	2.89	1.18	0.41	0.41	0.41	0.41
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-909	-845	-879	-855	-864	-867	-866	-858	-815	-828
Capital Expenditures (CapEx)	5.21	4.55	1.84	12	4.90	2.77	3.80	13	19	3.78
Debt-free, Cash-free Net Working Capital (DFCFNWC)	44	34	-0.09	9.60	24	12	5.28	12	40	23
Debt-free Net Working Capital (DFNWC)	615	560	504	468	491	436	311	324	253	281
Net Working Capital (NWC)	594	540	499	463	488	435	311	323	253	281
Net Nonoperating Expense (NNE)	-1.07	-1.51	-1.53	-2.27	13	29	-1.41	-4.14	2.74	-5.10
Net Nonoperating Obligations (NNO)	-909	-845	-879	-855	-864	-867	-866	-858	-815	-828
Total Depreciation and Amortization (D&A)	11	10	6.40	5.60	5.23	5.00	5.48	4.67	4.59	4.65
Debt-free, Cash-free Net Working Capital to Revenue	5.42%	5.52%	-0.03%	3.12%	8.21%	4.10%	1.84%	4.15%	14.36%	8.11%
Debt-free Net Working Capital to Revenue	76.54%	90.54%	138.24%	152.26%	171.54%	150.76%	108.15%	111.37%	91.07%	99.16%
Net Working Capital to Revenue	73.99%	87.20%	136.70%	150.78%	170.54%	150.35%	108.01%	111.23%	90.92%	99.01%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	30.17M	30.10M	29.54M	29.81M	30.01M	29.78M	29.77M	30.10M	30.42M	30.24M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	30.87M	30.96M	29.54M	29.81M	30.01M	29.78M	29.77M	30.10M	30.42M	30.24M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	29.44M	29.52M	29.70M	29.93M	29.63M	29.78M	29.92M	30.30M	30.59M	30.83M
Normalized Net Operating Profit after Tax (NOPAT)	0.35	-26	-17	-14	0.15	-106	-15	-13	-12	-11
Normalized NOPAT Margin	0.33%	-37.82%	-26.26%	-20.42%	0.18%	-150.04%	-23.66%	-18.63%	-16.66%	-14.82%
Pre Tax Income Margin	1.66%	-49.42%	-31.81%	-21.66%	8.10%	-205.94%	-21.98%	-15.79%	-25.83%	-10.55%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	6.54	0.00	0.00	0.00	-1,900.57	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	-6.00	0.00	0.00	0.00	-853.95	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-63.47	0.00	0.00	0.00	-3,293.36	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-76.02	0.00	0.00	0.00	-2,246.74	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	16.79%	52.38%	-270.48%	-127.08%	-48.10%	-14.30%	-14.60%	-14.81%	-13.43%	-0.51%

Frequently Asked Questions About Fulgent Genetics' Financials

When does Fulgent Genetics's financial year end?

According to the most recent income statement we have on file, Fulgent Genetics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Fulgent Genetics' net income changed over the last 2 years?

Fulgent Genetics' net income appears to be on an upward trend, with a most recent value of -$43.82 million in 2024, falling from $141.92 million in 2022. The previous period was -$175.24 million in 2023. Find out what analysts predict for Fulgent Genetics in the coming months.

What is Fulgent Genetics's operating income?

Fulgent Genetics's total operating income in 2024 was -$73.92 million, based on the following breakdown:

Total Gross Profit: $107.22 million
Total Operating Expenses: $181.13 million

How has Fulgent Genetics revenue changed over the last 2 years?

Over the last 2 years, Fulgent Genetics' total revenue changed from $618.97 million in 2022 to $283.47 million in 2024, a change of -54.2%.

How much debt does Fulgent Genetics have?

Fulgent Genetics' total liabilities were at $90.81 million at the end of 2024, a 11.0% decrease from 2023, and a 21.8% decrease since 2022.

How much cash does Fulgent Genetics have?

In the past 2 years, Fulgent Genetics' cash and equivalents has ranged from $55.14 million in 2024 to $97.47 million in 2023, and is currently $55.14 million as of their latest financial filing in 2024.

How has Fulgent Genetics' book value per share changed over the last 2 years?

Over the last 2 years, Fulgent Genetics' book value per share changed from 43.03 in 2022 to 37.05 in 2024, a change of -13.9%.

Related Companies

This page (NASDAQ:FLGT) was last updated on 5/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulgent Genetics (FLGT) Financials

Frequently Asked Questions About Fulgent Genetics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulgent Genetics (FLGT) Financials

Annual Income Statements for Fulgent Genetics

Quarterly Income Statements for Fulgent Genetics

Annual Cash Flow Statements for Fulgent Genetics

Quarterly Cash Flow Statements for Fulgent Genetics

Annual Balance Sheets for Fulgent Genetics

Quarterly Balance Sheets for Fulgent Genetics

Annual Metrics and Ratios for Fulgent Genetics

Quarterly Metrics and Ratios for Fulgent Genetics

Frequently Asked Questions About Fulgent Genetics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools